EN DE
Watch Translational Development Acquisition Corp. Ordinary Shares for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Translational Development Acquisition Corp. (TDAC) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Translational Development Acquisition Corp. stock $4.28, price $10.87, that is 60.6% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Financial Services US · ISIN KYG9008W1050

TD Translational Development Acquisition Corp. logo Thin data Nov 8, 2026

Translational Development Acquisition Corp.

TDAC · US
Very expensive, weak quality

Our calculation puts a fair price 61% below what the stock costs today.

Ranks above peers (6/8)
Profit last quarter 41% below a year ago.
Fair value $4.28 · Strongly overvalued
Quality 37/100
Negative free cash flow
Narrow moat 19/100 · thin data
Thin data
Watch Translational Development Acquisition Corp. Ordinary Shares for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.91 $10.00 Fair Value $4.28 Feb 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

21‑month range $10.00 – $10.91 · fair‑value band $3.21 – $5.35 · the $10.87 price screens above the $4.28 fair value. As of Nov 8, 2026.

Follow Translational Development Acquisition Corp. Ordinary Shares in your weekly email

Every Wednesday you see whether Translational Development Acquisition Corp. Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Show moreShow less

Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

Stock analysis

Translational Development Acquisition Corp. (TDAC) currently trades at $10.87, while our model-based Fair Value estimate is $4.28, 61% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $5.64 per share, and 0 of the 6 models we run sit above the $10.87 price.

Bear case: the Multiples group reads lowest at $2.23, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: $3.21 (bear) to $5.35 (bull), the price of $10.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Financial Services sector.

Translational Development Acquisition Corp. Ordinary Shares reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was $6.4M in FY2025.

Key figures

Market cap $210M Micro · P/E ratio 41.8 · EPS (TTM) $0.2600 · Return on assets (EBIT) −6,011% (4-year average) · EPS growth (YoY) −40.6% · Free cash flow −$608K · Net debt $170K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 4% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −51% fair-value upside, at −61%, TDAC screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($0.0900 to $5.96). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $3.21 Fair Value $4.28 Bull $5.35
Price $10.87 · Downside -60.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.2230 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
P/E Multiple $3.21 $4.28 $5.35 63
Residual Income $5.56 $5.64 $6.00 61
P/B Multiple $0.1400 $0.1800 $0.2300 55
All 6 models by family
Earnings-Based
Graham-Dodd $2.24 $5.96 $7.79 51
Lynch FV $1.15 $1.65 $2.14 48
Multiples
P/E Multiple $3.21 $4.28 $5.35 63
P/B Multiple $0.1400 $0.1800 $0.2300 55
Asset-Based
NCAV (Graham) $0.0600 $0.0900 $0.1300 51
Economic Profit
Residual Income $5.56 $5.64 $6.00 61

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 100
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 64
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

TDAC screens overvalued: fair value 61% below the price. Compare with Vylor Inc →

Compare Translational Development Acquisition Corp. Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 30 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −60.6% · Below median
Profitability
Return on assets 3.5% · Above median
Operating margin (12 months) 0.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Top 25%

Valuation Multiplesvs Shell Companies median · lower = cheaper

P/E (12 months) 41.8× · Cheaper than median
P/B 1.20× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Shell Companies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Metals Acquisition Corp MTAL $10.14 $17.24 +70% vs TDAC
AA Mission Acquisition Corp AAM $0.0300 $0.0390 +30% vs TDAC
TGE Value Creative Solutions Corp BEBE $10.07 $8.20 −19% vs TDAC
Lionheart III Corp LION $14.24 $9.72 −32% vs TDAC
Lionheart Holdings CUB $10.95 $5.41 −51% vs TDAC
Texas Ventures Acquisition III Corp TVACW $0.1501 $0.0680 −55% vs TDAC
Leapfrog Acquisition Corporation LFAC $10.10 $4.10 −59% vs TDAC
Berto Acquisition Corp TACO $10.50 $2.32 −78% vs TDAC
Vylor Inc VYLR $70.14 $14.28 −80% vs TDAC
Axiom Intelligence Acquisition Corp AXIN $10.40 $1.24 −88% vs TDAC

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Translational Development Acquisition Corp. Ordinary Shares: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Translational Development Acquisition Corp. Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/TDAC

Frequently asked questions

Is Translational Development Acquisition Corp. (TDAC) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $4.28 versus a price of $10.87, about 61% lower (overvalued).
What is the fair value of TDAC?
Our model-based fair value for Translational Development Acquisition Corp. is $4.28 (as of Nov 8, 2026), built from audited fundamentals. The current price: $10.87.
What is the quality score of TDAC?
Translational Development Acquisition Corp. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Translational Development Acquisition Corp. (TDAC)?
Our model-based price target is the fair value of $4.28 (as of Nov 8, 2026) from 6 valuation models. Cautious scenario $3.21, optimistic scenario $5.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Translational Development Acquisition Corp. Ordinary Shares stock forecast for 2026?
Our models put fair value at $4.28, about 61% lower versus a price of $10.87 (overvalued). Cautious scenario $3.21, optimistic scenario $5.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Translational Development Acquisition Corp. (TDAC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Translational Development Acquisition Corp. it is $4.28 per share (as of Nov 8, 2026), against a price of $10.87. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is Translational Development Acquisition Corp. Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 8, 2026, TDAC trades above its calculated fair value: price $10.87, fair value $4.28, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TDAC?
No. The price is what the market pays today ($10.87); the fair value is what the company's own numbers justify ($4.28). For Translational Development Acquisition Corp. the two are $6.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Translational Development Acquisition Corp. Ordinary Shares worth?
The market values Translational Development Acquisition Corp. at about $210M (market capitalisation, as of Nov 8, 2026). Per share that is $10.87; our models calculate a fair value of $4.28 per share.
What do the bullish and bearish scenarios say about TDAC?
Our models span a range for Translational Development Acquisition Corp.: cautious scenario $3.21, base $4.28, optimistic $5.35 per share (as of Nov 8, 2026, price $10.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TDAC?
Translational Development Acquisition Corp. trades at a price-to-earnings ratio of 41.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.28 is built from several models across several years. Other multiples: P/B 1.2.
How far is TDAC from its 52-week high?
Translational Development Acquisition Corp. trades at $10.87, at its 52-week high of $10.91 and 4% above the low of $10.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.28 is for.
Which stocks are comparable to Translational Development Acquisition Corp. Ordinary Shares?
From the same area (Financial Services) we also value Vylor Inc, Lionheart III Corp, AA Mission Acquisition Corp, Berto Acquisition Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Translational Development Acquisition Corp. Ordinary Shares stock attractive at the current price?
The data as of Nov 8, 2026: price $10.87, calculated fair value $4.28 (−61%), Quality Score 37/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TDAC calculated?
We run Translational Development Acquisition Corp. through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of $4.28 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Translational Development Acquisition Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Translational Development Acquisition Corp. (TDAC)?
The closing price on Nov 6, 2026 was $10.87. Our model-based fair value is $4.28, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Translational Development Acquisition Corp. Ordinary Shares right now?
The price sits above even our optimistic bull case ($5.35). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Translational Development Acquisition Corp.

How large is the market capitalisation of Translational Development Acquisition Corp. (TDAC)?
The market capitalisation of Translational Development Acquisition Corp. is $210M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Translational Development Acquisition Corp. (TDAC)?
Earnings per share at Translational Development Acquisition Corp. are $0.2600 (price ÷ EPS = P/E 41.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Translational Development Acquisition Corp. (TDAC)?
On an EBIT basis the return on assets of Translational Development Acquisition Corp. is −6,011% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at Translational Development Acquisition Corp. (TDAC)?
Earnings per share at Translational Development Acquisition Corp. are growing −40.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Translational Development Acquisition Corp. (TDAC) generate?
The free cash flow of Translational Development Acquisition Corp. is −$608K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Translational Development Acquisition Corp. (TDAC) carry?
The net debt of Translational Development Acquisition Corp. is $170K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Translational Development Acquisition Corp. Ordinary Shares in the live analysis

One click puts Translational Development Acquisition Corp. Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.